Equities research analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 15.8 %
Shares of NASDAQ:AKTX opened at $2.78 on Friday. The business’s 50-day simple moving average is $3.01 and its 200 day simple moving average is $2.79. Akari Therapeutics has a one year low of $1.08 and a one year high of $4.40.
About Akari Therapeutics
Featured Stories
- Five stocks we like better than Akari Therapeutics
- Transportation Stocks Investing
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- Investing In Automotive Stocks
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.